Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Protease Inhibitors
Lopinavir/Ritonavir (Kaletra, LPV/r)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 10
Generic Name (Abbreviation) Trade Name |
Formulation | Dosing Recommendationsa | Use in Pregnancy |
---|---|---|---|
Lopinavir/Ritonavir (LPV/r) Kaletra |
LPV/r (Kaletra) Tablets (Coformulated):
|
Standard Adult Dose:
With EFV or NVP (PI-Naive or PI-Experienced Patients):
|
Low placental transfer to fetus.b
No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects). Oral solution contains 42% alcohol and 15% propylene glycol and is not recommended for use in pregnancy. Once-daily LPV/r dosing is not recommended during pregnancy. |
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8). b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio: High: >0.6 Moderate: 0.3–0.6 Low: <0.3 Key to Acronyms: EFV = efavirenz; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NVP = nevirapine; PI = protease inhibitor; PK = pharmacokinetic; RTV = ritonavir |
Download Guidelines
- Section Only PDF (329 KB)
- Full Guideline PDF (3 MB)
- Recommendations Only PDF (211 KB)
- Tables Only PDF (388 KB)
Related Content
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive